Gerhard Koenig is a senior R&D leader with more than 28 years of experience in drug development. He co-founded US start-up Arkuda Therapeutics in early 2018, where he has since served as President & CEO and helped raise over USD 110 million in Series A & B financing rounds to develop therapies for neurological diseases. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics (NASDAQ GS: VIGL). Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer.

Gerhard received his PhD and MS degrees in molecular and cellular neurobiology with a minor in biochemistry, graduating summa laude from the University of Heidelberg, Germany.